Shenzhen Chipscreen Biosciences Co. Ltd. Class A

As of June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A carries a market capitalization of 11.66B, placing it among publicly traded companies globally. Its enterprise value stands at 11.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shenzhen Chipscreen Biosciences Co. Ltd. Class A's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A has 442.94M shares outstanding.

As of June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 110.35. The price-to-sales ratio is 10.82, and the price-to-book ratio stands at 4.57.

As of June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A trades at an EV/EBITDA multiple of 118.58 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 11.52 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 118.58 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 11.79B versus a market cap of 11.66B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A maintains a current ratio of 2.38, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 59.12, indicating elevated leverage, while an interest coverage ratio of 2.79 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A posted a return on equity (ROE) of 4.88, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 2.54, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.01M in revenue per employee across its workforce of 1,016.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.32 indicates how many times Shenzhen Chipscreen Biosciences Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A recorded an income tax benefit of -1.19M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 99.13M, leaving 100.32M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A's stock has declined approximately 24.86% over the past 52 weeks. The 50-day moving average sits at 25.76, while the 200-day moving average is 28.66.

Over the twelve months ended June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A generated 1.02B in revenue and converted that into 100.32M in net income, yielding earnings per share of 0.24. EBITDA reached 99.43M, while operating income came in at 155.79M.

As of June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A holds 1.38B in cash and equivalents against 1.51B in total debt, resulting in a net debt position of 553.21M. Total book value stands at 2.55B, with working capital of 1.13B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A posted a gross margin of 86.69, reflecting its pricing power and cost economics. The operating margin of 15.22 and net profit margin of 9.80 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A paid dividends of 0.12 per share. The dividend payout ratio of 50.95 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -6.71, meaning Shenzhen Chipscreen Biosciences Co. Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Shenzhen Chipscreen Biosciences Co. Ltd. Class A has an Altman Z-Score of 4.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.